Recombinant interferon in advanced breast cancer.
Fifteen patients with locally advanced refractory breast cancer have been treated with recombinant leucocyte interferon ( rIFN -alpha A) for up to 12 weeks. Toxicity was considerable with the initial dosage schedule employed but became acceptable after reducing the starting dose by 50%. Minor side effects occurred in all patients and major CNS toxicity in six. Nine patients showed some evidence of tumour regression at 4 weeks. Only two of these were still responding at 12 weeks. Response was unrelated to the length of previous history, oestrogen receptor status or previous responsiveness to cytotoxic or hormone therapy.
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000628:therapy*; D002493:Central Nervous System Diseases / Q000209:etiology; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006402:Hematologic Diseases / Q000209:etiology; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged
D007370:Interferon Type I